Earnings summaries and quarterly performance for HALOZYME THERAPEUTICS.
Executive leadership at HALOZYME THERAPEUTICS.
Board of directors at HALOZYME THERAPEUTICS.
Research analysts who have asked questions during HALOZYME THERAPEUTICS earnings calls.
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
4 questions for HALO
Also covers: ABCL, ABSI, ARWR +19 more
Michael DiFiore
Evercore ISI
4 questions for HALO
Also covers: AMGN, AMLX, BIIB +8 more
Jason Butler
JMP Citizens
3 questions for HALO
Also covers: ACAD, AQST, ATHA +9 more
Mitchell Kapoor
H.C. Wainwright & Co.
3 questions for HALO
Also covers: CTMX, INM, IONS +7 more
Sean Laaman
Morgan Stanley & Co.
3 questions for HALO
Also covers: ACAD, ARGX, AXSM +8 more
David Risinger
Leerink Partners
2 questions for HALO
Also covers: ABBV, AMGN, BMY +9 more
Jessica Fye
JPMorgan Chase & Co.
2 questions for HALO
Also covers: ALKS, ALNY, AMRN +23 more
Mohit Bansal
Wells Fargo & Company
2 questions for HALO
Also covers: ABBV, AMGN, BMRN +16 more
Adam Ferrari
J.P. Morgan
1 question for HALO
Also covers: ALKS, BMRN, IMCR
Cerena Chen
Wells Fargo & Company
1 question for HALO
Also covers: AMPH, AXSM
Corinne Johnson
Goldman Sachs
1 question for HALO
Also covers: ALT, AMLX, GERN +5 more
Daniel Smith
H.C. Wainwright & Co.
1 question for HALO
Also covers: AQST, RARE, SRPT
Karen Johnson
Goldman Sachs
1 question for HALO
Also covers: ALT
Morgan Gryga
Morgan Stanley
1 question for HALO
Also covers: ABSI, CERT, SAGE
Na Sun
JPMorgan Chase & Co.
1 question for HALO
Also covers: NVCR
Sadia Rahman
Wells Fargo
1 question for HALO
Also covers: AMGN, MLYS, TVTX
Recent press releases and 8-K filings for HALO.
Halozyme Secures German Injunction Against Merck's Keytruda SC Launch
HALO
Legal Proceedings
Product Launch
- A German court has issued a preliminary injunction against Merck & Co., blocking the launch and distribution of its subcutaneous Keytruda in Germany due to alleged patent infringement of Halozyme's MDASE delivery technology.
- The injunction specifically targets the subcutaneous formulation of Keytruda, with the intravenous version remaining unaffected and available to German patients.
- Halozyme has also filed lawsuits in the United States, asserting infringement of multiple MDASE patents, indicating a broader legal strategy to protect its intellectual property.
- Merck disputes the infringement claims, considering the patents invalid, and has initiated its own legal proceedings to challenge the patent's validity in Germany.
Dec 4, 2025, 10:58 PM
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
HALO
Legal Proceedings
Product Launch
- Halozyme Therapeutics announced that a German court granted a preliminary injunction against Merck, ordering it to halt distribution and offering of Keytruda SC in Germany due to infringement of one of Halozyme's MDASE™ patents.
- The preliminary injunction is appealable, and Merck has initiated separate nullity proceedings against the patent.
- Halozyme is also pursuing a patent infringement lawsuit against Merck in the U.S. federal district court regarding Keytruda SC (marketed as QLEX), alleging infringement of 15 MDASE™ patents.
- The MDASE™ patents are distinct from Halozyme's ENHANZE® licensing program, meaning the outcome of the infringement lawsuit will not impact ENHANZE® revenues or licensee abilities.
Dec 4, 2025, 6:26 PM
Halozyme Therapeutics Discusses Business Overview, Elektrofi Acquisition, and Financial Outlook
HALO
M&A
Guidance Update
Legal Proceedings
- Halozyme recently acquired Elektrofi for its HyperCon technology, aiming to expand its capabilities in small volume at-home delivery of biologic therapies.
- The company has upped its guidance, projecting revenue of $1.3-$1.375 billion and royalty growth of approximately 50% to $850-$880 million this year, with EBITDA growing almost 50% to $880-$930 million.
- Halozyme expects long-term durable revenues from its ENHANZE products, with most generating royalties until the mid-2030s and some into the early 2040s, and believes the Inflation Reduction Act (IRA) will have minimal to no impact on its future revenue streams.
- The company is engaged in litigation against Merck regarding 15 MDASE patents, seeking a permanent injunction and triple damages, noting this represents potential upside and no risk to ENHANZE royalties.
Dec 2, 2025, 6:20 PM
Halozyme Therapeutics Updates Guidance and Discusses Strategic Initiatives
HALO
Guidance Update
M&A
Legal Proceedings
- Halozyme Therapeutics raised its full-year guidance, expecting revenues of $1.3-$1.375 billion and EBITDA of $880-$930 million for the current year, driven by approximately 50% growth in royalties year-over-year.
- The company highlighted the recent Elektrofi acquisition for its HyperCon technology, which expands its SubQ delivery capabilities into small volume delivery, with IP extending to the mid-2040s and a similar mid-single-digit royalty structure to ENHANZE.
- Key ENHANZE products such as DARZALEX, PHESGO, and VYVGART Hytrulo are expected to continue driving revenue growth, with most ENHANZE royalties extending to at least 2030, many to the mid-2030s, and several into the early 2040s.
- Halozyme anticipates minimal to no impact from the IRA price negotiations on its future revenue stream, citing product characteristics like orphan indications or the availability of biosimilars.
- The ongoing Merck litigation concerns the MDASE patent portfolio, representing potential upside for Halozyme with no risk to existing ENHANZE royalties.
Dec 2, 2025, 6:20 PM
Halozyme Therapeutics Provides Business Overview and Updated Financial Guidance
HALO
Guidance Update
M&A
Legal Proceedings
- Halozyme Therapeutics has updated its guidance, projecting total revenue of $1.3 billion-$1.375 billion and royalty revenue of $850 million-$880 million for the current year, driven by approximately 50% growth in royalties and EBITDA.
- The company recently acquired Elektrofi for its Hypercon technology, which expands its subcutaneous delivery portfolio with small volume autoinjector capabilities and has intellectual property (IP) extending to the mid-2040s.
- Halozyme anticipates long-term durable revenues from its ENHANZE technology, with most product royalties extending to the mid-2030s and some into the early 2040s, and expects minimal to no impact from the Inflation Reduction Act (IRA) on its future revenue streams.
- The company is pursuing litigation against Merck for alleged infringement on 15 MDASE patents, seeking a permanent injunction and triple damages, noting this represents potential upside without risk to ENHANZE royalties.
Dec 2, 2025, 6:20 PM
Halozyme Completes Acquisition of Elektrofi
HALO
M&A
New Projects/Investments
Guidance Update
- Halozyme Therapeutics, Inc. has completed its acquisition of Elektrofi, Inc., a biopharmaceutical company specializing in the Hypercon™ ultra-high concentration microparticle formulation technology.
- The acquisition involved an upfront payment of $750 million and up to $150 million in contingent milestone payments, bringing the total consideration to up to $900 million.
- Halozyme projects royalty revenues from this acquisition to begin as early as 2030, with potential development and commercial milestone payments of up to $275 million from Elektrofi's existing partner programs expected to enter clinical development by year-end 2026 or earlier.
- The transaction is expected to be less than 5% dilutive to non-GAAP diluted EPS over the medium-term and will incur an incremental operating expense of approximately $55 million for full year 2026.
Nov 18, 2025, 1:50 PM
Halozyme and Merus Announce Collaboration for ENHANZE® Technology
HALO
New Projects/Investments
Product Launch
- Halozyme Therapeutics and Merus N.V. have entered into a global non-exclusive collaboration and license agreement.
- Merus has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody.
- Under the terms, Halozyme will receive an upfront payment, potential future milestone payments, and up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE® technology.
Nov 17, 2025, 12:00 PM
HALOZYME THERAPEUTICS, INC. Details Terms for Convertible Notes
HALO
Debt Issuance
M&A
Convertible Preferred Issuance
- Additional Interest will accrue on notes at a rate of 0.25% per annum for the first 90 days and 0.50% per annum thereafter if HALOZYME THERAPEUTICS, INC. fails to timely file required reports or if the notes are not "Freely Tradable".
- The Conversion Rate of the notes is subject to adjustments for various corporate actions, including stock dividends, splits, combinations, and distributions of rights, options, or warrants.
- In the event of a Make-Whole Fundamental Change, the Conversion Rate will be increased by Additional Shares based on the Stock Price and the Make-Whole Fundamental Change Effective Date.
- A Fundamental Change is defined by events such as a change in beneficial ownership exceeding 50% of voting power, the sale of substantially all assets, liquidation, or delisting of common stock.
Nov 12, 2025, 10:17 PM
Halozyme: FDA Approves DARZALEX Faspro® for High-Risk Smoldering Multiple Myeloma
HALO
Product Launch
New Projects/Investments
- Halozyme Therapeutics (HALO) announced that Johnson & Johnson received FDA approval for a new indication for DARZALEX Faspro®, which is co-formulated with Halozyme's ENHANZE® drug delivery technology.
- This approval designates DARZALEX Faspro® as the first and only approved treatment for high-risk smoldering multiple myeloma (HR-SMM) in adult patients.
- The new indication expands the therapeutic applications for DARZALEX Faspro with ENHANZE, reinforcing its role as a cornerstone therapy across all stages of multiple myeloma.
Nov 7, 2025, 1:30 PM
Halozyme Therapeutics, Inc. Announces Pricing of Convertible Senior Notes Offering
HALO
Debt Issuance
New Projects/Investments
- Halozyme Therapeutics, Inc. priced a private offering of $650.0 million aggregate principal amount of 0% convertible senior notes due 2031 and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032 on November 6, 2025.
- The company granted initial purchasers a 13-day option to buy an additional $100.0 million of each series of notes.
- The initial conversion price for both series is approximately $87.20 per share, representing a 27.5% premium over the common stock's closing price of $68.39 per share on November 6, 2025.
- Halozyme expects to receive approximately $1.274 billion in net proceeds, which it plans to use primarily to repurchase existing 2027 and 2028 convertible senior notes (~$1.020 billion) and fund capped call transactions (~$182.7 million), with the remainder for general corporate purposes.
Nov 7, 2025, 1:02 PM
Quarterly earnings call transcripts for HALOZYME THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more